Skip Navigation
Search Menu
Find an Expert

 


Julie Renee Brahmer, M.D.

Photo of Dr. Julie Renee Brahmer, M.D.

Interim director, Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins Bayview campus)

Associate Professor of Oncology

Female

Expertise: Clinical Trials, Lung Cancer, Medical Oncology , Mesothelioma

Request an Appointment

I live in Maryland

410-955-8964
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-502-7159
Fax: 410-614-9334

Background

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program and Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network.

Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993.  Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins.
 
Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She is in charge organizing the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach.Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma.
 
Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies.

She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation.

...read more

Titles

  • Interim director, Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins Bayview campus)
  • Director, Thoracic Oncology
  • Associate Professor of Oncology

Education

Degrees

  • MD, University of Nebraska Medical Center - GME (1993)

Residencies

  • The University of Utah / Internal Medicine (1997)

Fellowships

  • Johns Hopkins University School of Medicine / Oncology (2000)

Board Certifications

  • American Board of Internal Medicine / Medical Oncology (1999, 2010)

Research & Publications

Research Summary

Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma at SKCCC.  She is in charge organizing the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach.  She is also a part of the oncology pain team headed by Dr. Stuart Grossman.

Clinical Trial Keywords

Phase 1, mesothelioma, lung cancer

Selected Publications

View all on Pubmed

Brock, M.V.; Hooker, C.M.; Engels, E.A.; Moore, R.D.; Gillison, M.L.; Alberg, A.J.; Keruly, J.C.; Yang, S.C.; Heitmiller, R.F.; Baylin, S.B.; Herman, J.G.; Brahmer, J.R. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 2006 Sep;43(1):47-55.

Carducci, M.A.; Musib, L.; Kies, M.S.; Pili, R.; Truong, M.; Brahmer, J.R.; Cole, P.; Sullivan, R.; Riddle, J.; Schmidt, J.; Enas, N.; Sinha, V.; Thornton, D.E.; Herbst, R.S. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006 Sep 1;24(25):4092-4099.

Glazer, C.A.; Waldman, E.H.; Ansari-Lari, A.M.; Broussard, J.N.; Brahmer, J.; Tufano, R.P. Pathology quiz case 1. Metastatic mesothelioma involving the tongue. Arch Otolaryngol Head Neck Surg. 2006 Sep;132(9):1012, 1014-1015.

Jimeno, A.; Kulesza, P.; Kincaid, E.; Bouaroud, N.; Chan, A.; Forastiere, A.; Brahmer, J.; Clark, D.P.; Hidalgo, M. C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res. 2006 Feb 15;66(4):2385-2390.

Juergens, R.A.; Brahmer, J.R. Adjuvant treatment in non-small cell lung cancer: Where are we now? J Natl Compr Canc Netw. 2006 Jul;4(6):595-600.

Li, J.; Brahmer, J.; Messersmith, W.; Hidalgo, M.; Baker, S.D. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs. 2006 Jul;24(4):291-297.

Brahmer, J.R.; Ettinger, D.S. Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy. Respirology. 2007 May;12(3):320-325.

Hann, C.L.; Brahmer, J.R. Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when? Current treatment options in oncology. 2007 Feb;8(1):28-37.

Higginson, D.S.; Brahmer, J.; Tufano, R.P.; Bajaj, G.K. Pleural mesothelioma metastatic to tongue. J Clin Oncol. 2007 May 20;25(15):2133-2135.

Juergens, R.; Brahmer, J. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? Curr Oncol Rep. 2007 Jul;9(4):255-264.

Juergens, R.; Brahmer, J.; Ettinger, D. Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemother Pharmacol. 2007 Apr;59(5):621-629.

Li, J.; Cusatis, G.; Brahmer, J.; Sparreboom, A.; Robey, R.W.; Bates, S.E.; Hidalgo, M.; Baker, S.D. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther. 2007 Mar;6(3):432-438.

Madar, I.; Bencherif, B.; Lever, J.; Heitmiller, R.F.; Yang, S.C.; Brock, M.; Brahmer, J.; Ravert, H.; Dannals, R.; Frost, J.J. Imaging delta- and mu-opioid receptors by PET in lung carcinoma patients. J Nucl Med. 2007 Feb;48(2):207-213.

Taguchi, F.; Solomon, B.; Gregorc, V.; Roder, H.; Gray, R.; Kasahara, K.; Nishio, M.; Brahmer, J.; Spreafico, A.; Ludovini, V.; Massion, P.P.; Dziadziuszko, R.; Schiller, J.; Grigorieva, J.; Tsypin, M.; Hunsucker, S.W.; Caprioli, R.; Duncan, M.W.; Hirsch, F.R.; Bunn, P.A., Jr.; Carbone, D.P. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007 Jun 6;99(11):838-846.
Brahmer, J.R. Lung Cancer. In: Donehower, R.; Ettinger, D., editors. 5th Edition ed, Current Cancer Therapeutics. New York, NY: Churchill-Livingstone; 2008.

Fathi, A.T.; Brahmer, J.R. Chemotherapy for advanced stage non-small cell lung cancer. Seminars in thoracic and cardiovascular surgery. 2008 Fall;20(3):210-216.

Juergens, R.; Brahmer, J.R.; Spira, A.I. Effusions. 4th Edition ed, Clinical Oncology. New York, NY: Churchill-Livingstone; 2008.
Messersmith, W.A.; Jimeno, A.; Ettinger, D.; Laheru, D.; Brahmer, J.; Lansey, D.; Khan, Y.; Donehower, R.C.; Elsayed, Y.; Zannikos, P.; Hidalgo, M. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Dec;63(1):181-188.

Novello, S.; Brahmer, J.R.; Siegfried, J. Gender Related Differences in Lung Cancer. In: al, P.e., editor. 4th Edition ed, Lung Cancer: Principles and Practices. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

Ramalingam, S.S.; Dahlberg, S.E.; Langer, C.J.; Gray, R.; Belani, C.P.; Brahmer, J.R.; Sandler, A.B.; Schiller, J.H.; Johnson, D.H. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 1;26(1):60-65.

Rudin, C.M.; Liu, W.; Desai, A.; Karrison, T.; Jiang, X.; Janisch, L.; Das, S.; Ramirez, J.; Poonkuzhali, B.; Schuetz, E.; Fackenthal, D.L.; Chen, P.; Armstrong, D.K.; Brahmer, J.R.; Fleming, G.F.; Vokes, E.E.; Carducci, M.A.; Ratain, M.J. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 1;26(7):1119-1127.

Snyder, C.F.; Garrett-Mayer, E.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Symptoms, supportive care needs, and function in cancer patients: how are they related? Qual Life Res. 2008 Jun;17(5):665-677.

Socinski, M.A.; Novello, S.; Brahmer, J.R.; Rosell, R.; Sanchez, J.M.; Belani, C.P.; Govindan, R.; Atkins, J.N.; Gillenwater, H.H.; Pallares, C.; Tye, L.; Selaru, P.; Chao, R.C.; Scagliotti, G.V. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008 Feb 1;26(4):650-656.

Guarino, M.J.; Schneider, C.J.; Hosford, M.D.; Brahmer, J.R.; Rudin, C.M.; Finkenstein, F.G.; Philip-Norton, R.E.; Lue, H.; Weber, M.R.; Ettinger, D.S. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist. 2009;14(2):119-124.

Riely, G.J.; Rizvi, N.A.; Kris, M.G.; Milton, D.T.; Solit, D.B.; Rosen, N.; Senturk, E.; Azzoli, C.G.; Brahmer, J.R.; Sirotnak, F.M.; Seshan, V.E.; Fogle, M.; Ginsberg, M.; Miller, V.A.; Rudin, C.M. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jan 10;27(2):264-270.

Snyder, C.F.; Garrett-Mayer, E.; Blackford, A.L.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Concordance of cancer patients' function, symptoms, and supportive care needs. Qual Life Res. 2009 Oct;18(8):991-998.

Von Hoff, D.D.; LoRusso, P.M.; Rudin, C.M.; Reddy, J.C.; Yauch, R.L.; Tibes, R.; Weiss, G.J.; Borad, M.J.; Hann, C.L.; Brahmer, J.R.; Mackey, H.M.; Lum, B.L.; Darbonne, W.C.; Marsters, J.C., Jr.; de Sauvage, F.J.; Low, J.A. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-1172.

Amann, J.M.; Lee, J.W.; Roder, H.; Brahmer, J.; Gonzalez, A.; Schiller, J.H.; Carbone, D.P. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol. 2010 Feb;5(2):169-178.

Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.L.; Gilson, M.M.; Wang, C.; Selby, M.; Taube, J.M.; Anders, R.; Chen, L.; Korman, A.J.; Pardoll, D.M.; Lowy, I.; Topalian, S.L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 1;28(19):3167-3175.

Dahlberg, S.E.; Sandler, A.B.; Brahmer, J.R.; Schiller, J.H.; Johnson, D.H. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010 Feb 20;28(6):949-954.
Hann, C.L. Managing Risk-What if My Cancer Comes Back?: Jones and Bartlett; 2010.

Snyder, C.F.; Blackford, A.L.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. Qual Life Res. 2010 Aug;19(6):837-845.





Brahmer, J. R., and D. S. Ettinger. 2007. Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy. Respirology 12:320-5.

Brock, M. V., Hooker, C. M., Engels, E. A., Moore, R. D., Gillison, M. L., Alberg, A. J., Keruly, J. C., Yang, S. C., Heitmiller, R. F., Baylin, S. B., Herman, J. G. & Brahmer, J. R. (2006). Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 43, 47-55.

Brock, M. V., Hooker, C. M., Syphard, J. E., Westra, W., Xu, L., Alberg, A. J., Mason, D., Baylin, S. B., Herman, J. G., Yung, R. C., Brahmer, J., Rudin, C. M., Ettinger, D. S. & Yang, S. C. (2005). Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. J Thorac Cardiovasc Surg 129, 64-72.

Carducci, M. A., Musib, L., Kies, M. S., Pili, R., Truong, M., Brahmer, J. R., Cole, P., Sullivan, R., Riddle, J., Schmidt, J., Enas, N., Sinha, V., Thornton, D. E. & Herbst, R. S. (2006). Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24, 4092-9.

Fathi, A.T., and Brahmer, J.R. (2008). Chemotherapy for advanced stage non-small cell lung cancer. Seminars in thoracic and cardiovascular surgery 20, 210-216.

Glazer, C. A., Waldman, E. H., Ansari-Lari, A. M., Broussard, J. N., Brahmer, J. & Tufano, R. P. (2006). Pathology quiz case 1. Metastatic mesothelioma involving the tongue. Arch Otolaryngol Head Neck Surg 132, 1012, 1014-5.

Guarino, M.J., Schneider, C.J., Hosford, M.D., Brahmer, J.R., Rudin, C.M., Finkenstein, F.G., Philip-Norton, R.E., Lue, H., Weber, M.R., and Ettinger, D.S. (2008) Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist 14, 119-124..

Hann, C. L., and J. R. Brahmer. 2007. "Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?" Curr Treat Options Oncol 8:28-37.

Higginson, D. S., J. Brahmer, R. P. Tufano, and G. K. Bajaj. 2007. Pleural mesothelioma metastatic to tongue. J Clin Oncol 25:2133-5.

Jimeno, A., Kulesza, P., Kincaid, E., Bouaroud, N., Chan, A., Forastiere, A., Brahmer, J., Clark, D. P. & Hidalgo, M. (2006). C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res 66, 2385-90.

Juergens, R. A. & Brahmer, J. R. (2005). Adjuvant therapy for resected non-small-cell lung cancer: past, present, and future. Curr Oncol Rep 7, 248-54.

Juergens, R., A. Spira, and J. R. Brahmer. In Press. Effusions. In M. A. Abeloff, J. O. Armitage, and J. E. Niederhuber (ed.), Clinical Oncology 4th Edition. Churchill Livingstone.

Juergens, R., and J. Brahmer. 2007. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? Curr Oncol Rep 9:255-64.

Juergens, R., Brahmer, J. & Ettinger, D. (2006). Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemother Pharmacol.

Juergens, R., Brahmer, J.R., and Spira, A.I. (2008). Effusions. In: Clinical Oncology, New York, NY: Churchill-Livingstone. In Press.

Juergens, R., J. Brahmer, and D. Ettinger. 2007. Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemother Pharmacol 59:621-9.

Li, J., Brahmer, J., Messersmith, W., Hidalgo, M. & Baker, S. D. (2006). Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 24, 291-7.

Li, J., G. Cusatis, J. Brahmer, A. Sparreboom, R. W. Robey, S. E. Bates, M. Hidalgo, and S. D. Baker. 2007. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6:432-8.

Madar, I., B. Bencherif, J. Lever, R. F. Heitmiller, S. C. Yang, M. Brock, J. Brahmer, H. Ravert, R. Dannals, and J. J. Frost. 2007. Imaging delta- and mu-opioid receptors by PET in lung carcinoma patients. J Nucl Med 48:207-13.

Messersmith, W.A., Jimeno, A., Ettinger, D., Laheru, D., Brahmer, J., Lansey, D., Khan, Y., Donehower, R.C., Elsayed, Y., Zannikos, P., and Hidalgo, M. (2008). Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 63, 181-188.

Activities & Honors

Memberships

  • ACP
  • ASCO
  • IASLC

Videos & Media

Recent News Articles and Media Coverage

Is this you? Edit Profile